Pharmaceutical

MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset

MSD (Merck & Co) plans to start a Phase IIb/III trial for EyeBio’s lead candidate, Restoret, in diabetic macular oedema in H2.

Jul 14, 2024 - 04:00
MSD closes $1.3bn EyeBio acquisition, plans pivotal trial for lead asset
MSD (Merck & Co) plans to start a Phase IIb/III trial for EyeBio’s lead candidate, Restoret, in diabetic macular oedema in H2.
Read the original article

Tags:

Previous Article

Crossject secures funding from French Government for needle-free platform

Next Article

Explainer: Labour has been elected in the UK – now what?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

Sandoz’s Afqlir gains EC marketing authorisation for re...

Nov 19, 2024

Kidney doctors push to protect patients by including dialysis machines in emergency stockpile

Kidney doctors push to protect patients by including di...

Aug 7, 2023

STAT+: Eli Lilly’s Mounjaro succeeds in second weight loss study, paving way for FDA review

STAT+: Eli Lilly’s Mounjaro succeeds in second weight l...

Apr 27, 2023